LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Blood-Based Biomarkers Validated for Mild Cognitive Impairment

By LabMedica International staff writers
Posted on 20 Jan 2014
Print article
Image: TaqMan Reverse Transcription Kit for microRNA (Photo courtesy of Life technologies).
Image: TaqMan Reverse Transcription Kit for microRNA (Photo courtesy of Life technologies).
A minimally invasive test is essential for the early detection and monitoring of Alzheimer's and other neurodegenerative diseases for both drug development and planning of patient care.

Plasma micro ribonucleic acid biomarkers have been used for the detection of mild cognitive impairment (MCI) which is a condition characteristic of early stages of many neurodegenerative diseases, including Alzheimer's disease.

Scientists from the molecular diagnostic company DiamiR, LLC, (Princeton, NJ, USA) working with colleagues from the Roskamp Institute (Sarasota, FL, USA) obtained plasma samples from 50 MCI patients and 50 age matched controls (AMC). The miRNA isolation and quantitative real-time polymerase chain reaction (qRT-PCR) analysis were performed by Asuragen Inc. (Austin, TX, USA). Single target qRT-PCR was performed using the TaqMan Reverse Transcription Kit and miRNA specific stem-loop primers (Applied Biosystems; Foster City, CA, USA).

The investigators reported that two families of microRNA biomarkers, miR-132 and miR-134 families, detect MCI with the overall accuracy of 96% and 87% respectively, when plasma samples of MCI patients are compared to plasma samples of age/gender matched control subjects. The two families of biomarkers were identified among neurite/synapse enriched microRNAs and paired with brain-enriched microRNA normalizers using proprietary algorithms and software developed at DiamiR. The biomarkers are believed to reflect pathological processes underlying synaptic dysfunction and destruction characteristic of an early, preclinical stage of dementia development.

Samuil R. Umansky MD, PhD, DSc, president and chief scientific officer of DiamiR, said, “The results of this study are highly encouraging for the development of a test for early detection of Mild Cognitive Impairment, a condition affecting millions of Americans. The reported data validates DiamiR's innovative approach of using organ-enriched microRNAs for early detection of a pathology, when therapeutic interventions as well as life style changes are much more likely to have a meaningful positive impact.” The study was published on December 22, 2013, in the journal Aging.

Related Links:
DiamiR LLC
Roskamp Institute
Applied Biosystems

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more